Minimally invasive hysterectomy may require the use of morcellation to remove the uterus. In the presence of unexpected sarcoma, morcellation risks disseminating malignant cells and worsening survival outcomes. As a consequence, in 2014 the US Food and Drug Administration (FDA) issued a black box warning against the use of power morcellator for the treatment of uterine fibroids. However, the proportion of unexpected sarcoma at the time of hysterectomy for presumed benign indication remains unclear.

Incidence of Sarcoma in Patients Undergoing Hysterectomy for Benign Indications: A Population-Based Study

Angioni, Stefano
Membro del Collaboration Group
;
2019-01-01

Abstract

Minimally invasive hysterectomy may require the use of morcellation to remove the uterus. In the presence of unexpected sarcoma, morcellation risks disseminating malignant cells and worsening survival outcomes. As a consequence, in 2014 the US Food and Drug Administration (FDA) issued a black box warning against the use of power morcellator for the treatment of uterine fibroids. However, the proportion of unexpected sarcoma at the time of hysterectomy for presumed benign indication remains unclear.
2019
Olmsted County; hysterectomy; morcellation; uterine fibroids; uterine sarcoma
File in questo prodotto:
File Dimensione Formato  
Mutinu Am J Ob Gyn 2019.pdf

Solo gestori archivio

Tipologia: versione editoriale (VoR)
Dimensione 508.59 kB
Formato Adobe PDF
508.59 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/256131
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 33
social impact